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SHORT COMMUNICATION
Angiotensin II: a hormone that affects lipid
metabolism in adipose tissue
GH Goossens1, EE Blaak1, P Arner2, WHM Saris1 and MA van Baak1
1Department of Human Biology, Nutrition and Toxicology Research Institute Maastricht (NUTRIM), Maastricht University,
Maastricht, The Netherlands and 2Department of Medicine, Huddinge University Hospital, Karolinska Institute, Stockholm,
Sweden
Background: Alterations in adipose tissue lipolysis may contribute to the pathophysiology of obesity and insulin resistance. We
examined the effects of angiotensin II (Ang II) on abdominal subcutaneous adipose tissue lipolysis in humans.
Methods and results: First, adipocytes obtained from nine normal weight and seven obese subjects were stimulated with Ang II
(1014–106 M). Glycerol concentration in the medium, used as an indicator of adipocyte lipolysis, was significantly reduced
(B20%) after Ang II stimulation in adipocytes from normal weight (P¼ 0.04) and obese subjects (Po0.001). Based on these
observations, adipocytes of seven additional obese subjects were stimulated with lower doses of Ang II (1017–106 M) in the
presence and absence of Ang II type 1 (AT1) receptor blockade. Lipolysis was dose dependently inhibited byB20 to 25% after
Ang II stimulation (P¼0.001). AT1 receptor blockade completely abolished the Ang II-induced effects (P¼0.35).
Conclusion: Ang II directly inhibits abdominal subcutaneous adipocyte lipolysis in normal weight and obese subjects via the AT1
receptor.
International Journal of Obesity advance online publication, 16 May 2006; doi:10.1038/sj.ijo.0803388
Keywords: angiotensin II; Ang II type 1 receptor; lipolysis; adipose tissue
Introduction
Abdominal obesity is strongly associated with insulin
resistance. Part of this association may be explained by
adipose tissue products that exert autocrine, paracrine and/
or endocrine effects that may affect metabolism.1–3
A functional renin–angiotensin system (RAS) is present in
human adipose tissue,4–6 and local generation of angiotensin
II (Ang II), the effector molecule of the RAS, by human
(pre)adipocytes has been demonstrated.7 The adipose tissue
RAS may be involved in obesity-related disorders, such as
insulin resistance,8,9 possibly through an effect on adipocyte
differentiation.10,11 Furthermore, direct lipogenic effects of
Ang II in human adipocytes have been shown,12 and recent
data from our laboratory suggest that Ang II may inhibit
lipolysis in vivo in human adipose tissue and skeletal
muscle.13 However, no conclusions about the magnitude of
the observed antilipolytic effects of Ang II could be drawn
from these findings, as the Ang II-induced decrease in tissue
blood flow may have masked direct effects on lipolysis to
some extent. The objective of the present study was to
investigate for the first time the direct effects of Ang II on
abdominal subcutaneous adipose tissue lipolysis in vitro in
normal weight and obese subjects.
Materials and methods
Nine normal weight and seven obese male subjects partici-
pated in the first study. Seven additional obese subjects
participated in a second experiment. Characteristics of the
subjects are summarized in Table 1. The Medical-Ethical
Committee of Maastricht University approved the study
protocol and all subjects gave written informed consent
before participating in the study.
Protocol
Abdominal subcutaneous adipose tissue (B2 g) was obtained
by needle aspiration under local anesthesia after an over-
night fast. Adipocytes were isolated from the subcutaneous
fat tissue specimen as described previously.14 Firstly, diluted
suspensions of adipocytes (B5000–10 000 cells/incubation)
from normal weight and obese subjects were incubated withReceived 18 November 2005; revised 5 April 2006; accepted 8 April 2006
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Ang II (1014–106 M; Sigma-Aldrich, Zwijndrecht, The
Netherlands) for 2 h at 371C in Krebs–Ringer phosphate
buffer. Thereafter, incubation medium was immediately
frozen in liquid nitrogen and stored at 801C until analysis.
Glycerol concentration in the medium, determined using a
sensitive automated bioluminescence method,15 was used as
an indicator of lipolysis.
Adipocytes of an additional group of obese subjects were
stimulated with lower Ang II concentrations (1017–106 M)
in the presence and absence of AT1 receptor blockade (10
–4
M
losartan; MSD, Haarlem, The Netherlands). Furthermore,
adipocytes were incubated with N6-(2-phenylisopropyl)ade-
nosine (PIA: 100 nM) (Sigma-Aldrich) as a control point for
maximal inhibition of lipolysis in the incubation system.
Statistical analysis. Data are mean7standard error of the
mean (s.e.m.). Lipolytic rates are presented as relative
changes from baseline because of interindividual variation
in baseline glycerol concentrations. Effects of Ang II were
compared by two-way repeated measures analysis of variance
(ANOVA), using dose as within-subject factor and group or
treatment as between-subject factor. One-way repeated
measures ANOVA was performed to identify dose effects.
Po0.05 was considered to be statistically significant, using
SPSS 10.1 (Chicago, IL, USA).
Results and discussion
Basal lipolytic rates were not significantly different between
normal weight and obese subjects (4.871.1 vs
11.475.1mmol107 cells12 h incubation1, respectively,
P¼0.24). Ang II significantly inhibited adipocyte lipolysis in
normal weight (P¼0.04) and obese subjects (Po0.001)
(Figure 1a), with no differences between groups (P¼0.40).
In the second experiment, basal lipolytic rate was
5.071.0 mmol/107 cells/2 h incubation. Ang II dose depen-
dently inhibited lipolysis by B20–25% (P¼0.001), and this
effect was completely abolished by AT1 receptor blockade
(P¼ 0.35) (Figure 1b).
These findings demonstrate that Ang II inhibits lipolysis
through the AT1 receptor in abdominal subcutaneous adipo-
cytes in normal weight and obese subjects. PIA, used as a
control point for maximal inhibition of lipolysis in the
incubation system,16 reduced the lipolytic rate by B40%
(Po0.01) (data not shown). Therefore, the observedB20–25%
reduction of glycerol release after Ang II stimulation reflects a
substantial inhibition of lipolysis. The normal circulating Ang
II concentration is 10 pM.17 It has previously been shown that
Ang II concentrations areB2–3-fold higher in the incubation
medium of (pre)adipocytes than in the circulation.4,7 Because
stimulation of adipocytes with physiological concentrations
of Ang II evoked near-maximal inhibition of lipolysis in the
present experiments, Ang II may not play an important role in
the regulation of adipocyte lipolysis. Instead, Ang II may exert
a tonic suppression of adipocyte lipolysis.
Figure 1 (a) Effects of Ang II stimulation on glycerol release from abdominal
subcutaneous adipocytes from nine normal weight and seven obese subjects.
Ang II reduced glycerol release both in normal weight (P¼ 0.04 by one-way
repeated-measures ANOVA) and obese subjects (Po0.001 by one-way
repeated-measures ANOVA), with no differences between groups (P¼0.40
by two-way repeated-measures ANOVA). Values are means7s.e.m. (b) Effects
of Ang II stimulation on glycerol release from abdominal subcutaneous
adipocytes from seven obese subjects in the presence and absence of AT1
receptor blockade (104 M). Glycerol release was dose dependently reduced
during stimulation with Ang II (P¼0.001 by one-way repeated-measures
ANOVA). Ang II had no significant effects on lipolysis in the presence of AT1
receptor blockade (P¼0.35 by one-way repeated-measures ANOVA). Values
are means7s.e.m.
Table 1 Subjects’ characteristics
Normal weight Obese (study 1) Obese (study 2)
Age (years) 5472 5172 5274
Weight (kg) 76.571.9 112.876.4* 109.176.3#
Height (m) 1.7870.03 1.7870.02 1.8170.02
BMI (kg/m2) 24.370.4 35.571.8* 33.371.9#
Body fat (%) 22.971.3 34.672.7* 34.473.1#
Abbreviation: BMI, body mass index. Values are means7s.e.m. *P¼0.001 vs
normal weight by unpaired t-test; #Po0.005 vs normal weight by unpaired t-test.
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The present findings are in line with previous observations
suggesting that Ang II inhibits adipose tissue lipolysis in
humans.13 In contrast, no effect of Ang II on insulin-induced
suppression of lipolysis was observed in obese women.18 In
addition to methodological differences compared with the
present study, insulin may have masked a less pronounced
antilipolytic effect of Ang II. In a rat model for increased RAS
activity in cachectic patients with advanced heart failure,
lipolysis was increased in some but not all fat depots.19
Because expression of (anti)lipolytic receptors differs be-
tween species,19 and the high Ang II concentrations
activated the sympathetic nervous system, it is difficult to
extrapolate these findings to Ang II effects on adipocyte
lipolysis in humans.
It has been shown that Ang II exerts lipogenic effects in
human adipocytes12 and inhibits adipocyte differentiation.11
Although Ang II effects in adipose tissue may not be
involved in the expansion of fat mass, they may contribute
to a reduced buffering capacity for lipid storage in adipose
tissue in the long term, leading to an excessive influx of
lipids to other tissues.10
In conclusion, Ang II inhibits lipolysis via the AT1 receptor
in abdominal subcutaneous adipocytes from normal weight
and obese subjects. The present findings support the concept
that the RAS in adipose tissue participates directly in fat
metabolism and may contribute to the metabolic distur-
bances seen in obesity. This study was not designed to
examine underlying signalling pathways, but focused on
lipolysis as cellular end point. Identification of the under-
lying mechanisms for the antilipolytic effect of Ang II in
human adipocytes may provide better insight into possible
interactions between (anti)lipolytic pathways.
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